Enhanced Anticancer Performance of Eco-Friendly-Prepared Mo-ZnO/RGO Nanocomposites: Role of Oxidative Stress and Apoptosis
Overview
Affiliations
ZnO nanoparticles (NPs) have attracted great attention in cancer therapy because of their novel and tailorable physicochemical features. Pure ZnO NPs, molybdenum (Mo)-doped ZnO NPs, and Mo-ZnO/reduced graphene oxide nanocomposites (Mo-ZnO/RGO NCs) were prepared using a facile, inexpensive, and eco-friendly approach using date palm ( L.) fruit extract. Anticancer efficacy of green synthesized NPs/NCs was examined in two different cancer cells. The potential mechanism of the anticancer activity of green synthesized NPs/NCs was explored through oxidative stress and apoptosis. The syntheses of pure ZnO NPs, Mo-ZnO NPs, and Mo-ZnO/RGO NCs were confirmed by X-ray diffraction (XRD), transmission electron microscopy (TEM), scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDS), and photoluminescence (PL). Dynamic light scattering (DLS) study indicated the excellent colloidal stability of green prepared samples. Mo-ZnO/RGO NCs exhibited threefold higher anticancer activity in human colon (HCT116) and breast (MCF7) cancer cells as compared to pure ZnO NPs. The anticancer activity of Mo-ZnO/RGO NCs was mediated through reactive oxygen species, p53, and the caspase-3 pathway. Moreover, cytocompatibility of Mo-ZnO/RGO NCs in human normal colon epithelial (NCM460) and normal breast epithelial cells (MCF10A) was much better than those of pure ZnO NPs. Altogether, green stabilized Mo-ZnO/RGO NCs exhibited enhanced anticancer performance and improved cytocompatibility because of green mediated good synergism between ZnO, Mo, and RGO. This study suggested the high nutritional value fruit-based facile preparation of ZnO-based nanocomposites for cancer therapy.
Mahnoor , Malik K, Kazmi A, Sultana T, Raja N, Bibi Y Heliyon. 2025; 11(3):e41654.
PMID: 39916856 PMC: 11800088. DOI: 10.1016/j.heliyon.2025.e41654.
Impact of metallic nanoparticles on gut microbiota modulation in colorectal cancer: A review.
Kumar A, Pramanik J, Batta K, Bamal P, Gaur M, Rustagi S Cancer Innov. 2024; 3(6):e150.
PMID: 39398260 PMC: 11467490. DOI: 10.1002/cai2.150.
Saadh M, Jafar N, Altalbawy F, Sharma P, Kumar A, Alamir H RSC Adv. 2024; 14(34):24473-24482.
PMID: 39108958 PMC: 11299157. DOI: 10.1039/d4ra03758h.
Mongy Y, Shalaby T Sci Rep. 2024; 14(1):13470.
PMID: 38866790 PMC: 11169510. DOI: 10.1038/s41598-024-63258-7.
Naiel B, Fawzy M, Mahmoud A, Halmy M Sci Rep. 2024; 14(1):13459.
PMID: 38862646 PMC: 11167042. DOI: 10.1038/s41598-024-63459-0.